Who
Michael S. Weiss
Executive Vice Chairman
Company insider
Files Form 4 as: Executive Vice Chairman, Fortress Biotech; CEO, TG Therapeutics; Director, Checkpoint Therapeutics; Director, Mustang Bio; Director, Avenue Therapeutics; Chief Executive Officer, Keryx Biopharmaceuticals; Director, XTL Biopharmaceuticals.
In numbers
- Trades disclosed
- 311
- Buys
- 11
- Sells
- 32
- Bought
- $4.7M
- Sold
- $17.6M
- Companies
- 7
- Companies where not an officer
- 4
- First trade
- 2 Jan 2006
- Last trade
- 18 Mar 2026
- Last filed
- 20 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Mar 2026filed 20 Mar 2026 | FBIO Fortress BiotechBiotechnology | SEC FORM 4 Code A | —475,424 at $0.00 | filing |
| 18 Mar 2026filed 20 Mar 2026 | FBIO Fortress BiotechBiotechnology | SEC FORM 4 Code A | —475,424 at $0.00 | filing |
| 8 Jan 2026filed 9 Jan 2026 | TGTX TG TherapeuticsBiotechnology | SEC FORM 4 Code A | —622,000 at $0.00 | filing |
| 8 Jan 2026filed 9 Jan 2026 | TGTX TG TherapeuticsBiotechnology | SEC FORM 4 Code A | —622,000 at $0.00 | filing |
| 5 Nov 2025filed 7 Nov 2025 | TGTX TG TherapeuticsBiotechnology | SEC FORM 4 Code G | —3,865,126 at $0.00 | filing |
| 5 Nov 2025filed 7 Nov 2025 | TGTX TG TherapeuticsBiotechnology | SEC FORM 4 Code G | —803,717 at $0.00 | filing |
| 30 May 2025filed 30 May 2025 | Checkpoint Therapeutics | SEC FORM 4 Code U | —187,007 | filing |
| 29 May 2025filed 30 May 2025 | Checkpoint Therapeutics | SEC FORM 4 Code A | $65K50,000 at $1.29 | filing |
| 28 May 2025filed 30 May 2025 | Checkpoint Therapeutics | SEC FORM 4 Code A | —12,195 at $0.00 | filing |
| 29 Jan 2025filed 30 Jan 2025 | TGTX TG TherapeuticsBiotechnology | SEC FORM 4 Code A | —750,000 at $0.00 | filing |
| 1 Jan 2025filed 3 Jan 2025 | FBIO Fortress BiotechBiotechnology | SEC FORM 4 Code A | —454,153 at $0.00 | filing |
| 13 Dec 2024filed 17 Dec 2024 | Checkpoint Therapeutics | SEC FORM 4 Code A | —12,638 at $0.00 | filing |
| 14 May 2024filed 16 May 2024 | Checkpoint Therapeutics | SEC FORM 4 Code A | —32,051 at $0.00 | filing |
| 14 May 2024filed 16 May 2024 | Checkpoint Therapeutics | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 6 Jan 2024filed 8 Jan 2024 | TGTX TG TherapeuticsBiotechnology | SEC FORM 4 Code A | —1,001,908 at $0.00 | filing |
| 1 Jan 2024filed 3 Jan 2024 | FBIO Fortress BiotechBiotechnology | SEC FORM 4 Code A | —216,465 at $0.00 | filing |
| 14 Nov 2023filed 16 Nov 2023 | FBIO Fortress Biotechoption or derivative · Biotechnology | SEC FORM 4 Code P | —147,058 at $0.00 | filing |
| 14 Nov 2023filed 16 Nov 2023 | FBIO Fortress BiotechBiotechnology | SEC FORM 4 Bought | $250K147,058 at $1.70 | filing |
| 11 Aug 2023filed 14 Aug 2023 | TGTX TG TherapeuticsBiotechnology | SEC FORM 4 Bought | $1.0M100,000 at $10.13 | filing |
| 5 Jul 2023filed 7 Jul 2023 | MBIO Mustang BioBiotechnology | SEC FORM 4 Code A | —7,246 at $0.00 | filing |
News
Head to Head Analysis: Fortress Biotech (NASDAQ:FBIO) versus 60 Degrees Pharmaceuticals (NASDAQ:SXTP)FBIO · tickerreport.com · 17 Oct 2026Critical Survey: Fortress Biotech (NASDAQ:FBIO) vs. 60 Degrees Pharmaceuticals (NASDAQ:SXTP)FBIO · tickerreport.com · 11 Oct 2026
0 headlines in the last 90 days name Michael S. Weiss; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.